Last reviewed · How we verify
Eosinophilic esophagitis
Approved treatments
- Dupixent · Regeneron
Dupixent blocks the interleukin-4 receptor, a key player in the immune system's inflammatory response. - Pulmicort Respules · AstraZeneca K.K.
Pipeline
- CROMOLYN SODIUM — Phase 4
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Eosinophilic esophagitis patent landscape — cliff calendar, originator estates, attackable patents
- Eosinophilic esophagitis treatment landscape brief
- Eosinophilic esophagitis treatment updates RSS
Frequently asked questions about Eosinophilic esophagitis
What drugs treat Eosinophilic esophagitis?
Tracked treatments include Dupixent, Pulmicort Respules.
What is the treatment for Eosinophilic esophagitis?
Standard treatment for Eosinophilic esophagitis includes Dupixent, Pulmicort Respules. See the treatment landscape page for first-line, second-line and salvage options.
What new drugs are in development for Eosinophilic esophagitis?
1 pipeline drugs tracked. Top candidates: CROMOLYN SODIUM.
Related
- Treatment landscape: Eosinophilic esophagitis patent cliff · Eosinophilic esophagitis CI report
- Treatment: Dupixent · Regeneron
- Treatment: Pulmicort Respules · AstraZeneca K.K.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing